Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase

Surgery

Volumn 143, Issue 1, 2008, Pages 58-71

  Mariette, Christophe ^a,b   Piessen, Guillaume ^a,b   Leteurtre, Emmanuelle ^a,b   Hémon, Brigitte ^a   Triboulet, Jean Pierre ^b   Van Seuningen, Isabelle ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; DEOXYCHOLIC ACID; GLYCOCHOLATE SODIUM; GLYCOCHOLIC ACID; MUCIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID;

ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; BILE ACIDS AND SALTS; CA-15-3 ANTIGEN; CELL LINE, TUMOR; DEOXYCHOLIC ACID; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; HUMANS; IMMUNOHISTOCHEMISTRY; MUCINS; MUCOUS MEMBRANE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TAUROCHOLIC ACID; TRANSFECTION; UP-REGULATION;

EID: 37249072266     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.07.043     Document Type: Article

References (56)

1. DeMeester S.R. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 13 (2006) 2-30
2. Mariette C., Finzi L., Piessen G., Van Seuningen I., and Triboulet J.-P. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 29 (2005) 39-45
3. Wild C.P., and Hardie L.J. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nature Rev Cancer 3 (2003) 676-685
4. Ye W., Chow W.H., Lagergren J., Yin L., and Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 121 (2001) 1286-1293
5. Warson C., Van De Bovenkamp J.H., Korteland-Van Male A.M., Buller H.A., Einerhand A.W., Ectors N.L., et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 33 (2002) 660-668
6. Gillen P., Thornton J., Byrne P.J., Walsh T.N., and Hennessy T.P. Implications of upright gastro-oesophageal reflux. Br J Surg 81 (1994) 239-240
7. Jankowski J.A., Harrison R.F., Perry I., Balkwill F., and Tselepis C. Barrett's metaplasia. Lancet 356 (2000) 2079-2085
8. Sato T., Miwa K., Sahara H., Segawa M., and Hattori T. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens. Anticancer Res 22 (2002) 39-44
9. Goldstein S.R., Yang G.Y., Curtis S.K., Reuhl K.R., Liu B.C., Mirvish S., et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 18 (1997) 2265-2270
10. Montgomery E., Goldblum J.R., Greenson J.K., Haber M.M., Lamps L.W., Lauwers G.Y., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 (2001) 379-388
11. Hollingsworth M.A., and Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4 (2004) 45-60
12. Arul G.S., Moorghen M., Myerscough N., Alderson D.A., Spicer R.D., and Corfield A.P. Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut 47 (2000) 753-761
13. Corfield A.P., Myerscough N., Longman R., Sylvester P., Arul S., and Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 47 (2000) 589-594
14. Gendler S.J. MUC1: the Renaissance molecule. J Mammary Gland Biol Neoplasia 6 (2001) 339-353
15. von Mensdorff-Pouilly S., Snijdewint F.G.M., Verstraeten A.A., Verheijen R.H.M., and Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 15 (2000) 343-356
16. Baldus S.E., Engelmann K., and Hanisch F.-G. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41 (2004) 189-231
17. Dube D.H., Prescher J.A., Quang C.N., and Bertozzi C.R. Probing mucin-type O-linked glycosylation in living animals. Proc Natl Acad Sci U S A 103 (2006) 4819-4824
18. Guillem P., Billeret V., Buisine M.P., Flejou J.-F., Lecomte-Houcke M., Degand P., et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 88 (2000) 856-861
19. Glickman J.N., Shahsafaei A., and Odze R.D. Mucin core peptide expression can help differentiate Barrett's oesophagus from intestinal metaplasia of the stomach. Am J Surg Pathol 27 (2003) 1357-1365
20. Bax D.A., Einerhand A.W.C., van Dekken H., Blok P., Siersema P.D., Kuipers E.J., et al. MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio. J Clin Pathol 57 (2004) 1267-1272
21. Mariette C., Perrais M., Leteurtre E., Jonckheere N., Hemon B., Pigny P., et al. Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. Biochem J 377 (2004) 701-708
22. Song S., Byrd J.C., Koo J.S., and Bresalier R.S. Bile acids induce MUC2 overexpression in human colon carcinoma cells. Cancer 103 (2005) 1606-1614
23. Piessen G., Jonckheere N., Vincent A., Hemon B., Ducourouble M.-P., Copin M.-C., et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem J 402 (2007) 81-91
24. Van Seuningen I., Perrais M., Pigny P., Porchet N., and Aubert J.-P. Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells. Biochem J 348 (2000) 675-686
25. Lan M., Batra S.K., Qi W.-N., Metzgar R.S., and Hollingsworth M.A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 265 (1990) 15294-15299
26. Mesquita P., Jonckheere N., Almeida R., et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem 278 (2003) 51549-51556
27. Matuoka K., Chen K.Y., and Takenawa T. A positive role of phosphatidylinositol 3-kinase in aging phenotype expression in cultured human diploid fibroblasts. Arch Gerontol Geriatr 36 (2003) 203-219
28. McIlhinney R.A.J., Patel S., and Gore M.E. Monoclonal antibodies recognizing epitopes carried on both glycolipids and glycoproteins of the human milk fat globule membrane. Biochem J 227 (1985) 155-162
29. Perrais M., Pigny P., Copin M.-C., Aubert J.-P., and Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 277 (2002) 32258-32267
30. Beuers U. Effects of bile acids on hepatocellular signaling and secretion. Yale J Biol Med 70 (1997) 341-346
31. Brady L.M., Beno D.W., and Davis B.H. Bile acid stimulation of early growth response gene and mitogen-activated protein kinase is protein kinase C-dependent. Biochem J 316 (1996) 765-769
32. Rust C., Karnitz L.M., Paya C.V., Moscat J., Simari R.D., and Gores G.J. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275 (2000) 20210-20216
33. Jaiswal K., Tello V., Lopez-Guzman C., Nwariaku F., Anthony T., and Sarosi Jr. G.A. Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery 136 (2004) 160-168
34. Raina D., Kharbanda S., and Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 279 (2004) 20607-20612
35. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
36. Tullai J.W., Schaffer M.E., Mullenbrock S., Kasif S., and Cooper G.M. Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways. J Biol Chem 279 (2004) 20167-20177
37. Kim S., Domon-Dell C., Wang Q., Chung D.H., Di Cristofano A., Pandolfi P.P., et al. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 123 (2002) 1163-1178
38. Abdel-Latif M.M., O'Riordan J., Windle H.J., Carton E., Ravi N., Kelleher D., et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239 (2004) 491-500
39. Jenkins G.J., Harries K., Doak S.H., Wilmes A., Griffiths A.P., Baxter J.N., et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 25 (2004) 317-323
40. Jung D., and Kullak-Ublick G.A. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37 (2003) 622-631
41. Kazumori H., Ishihara S., Rumi M.A., Kadowaki Y., and Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55 (2006) 16-25
42. Kaur B.S., Ouatu-Lascar R., Omary M.B., and Triadafilopoulos G. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol 278 (2000) G1000-G1009
43. Garewal H., Bernstein H., Bernstein C., Sampliner R., and Payne C. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res 56 (1996) 1480-1483
44. Fein M., Fuchs K.H., Stopper H., Diem S., and Herderich M. Duodenogastric reflux and foregut carcinogenesis: analysis of duodenal juice in a rodent model of cancer. Carcinogenesis 21 (2000) 2079-2084
45. Gillen P., Keeling P., Byrne P.J., Healy M., O'Moore R.R., and Hennessy T.P. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg 75 (1988) 540-543
46. Nehra D., Howell P., Williams C.P., Pye J.K., and Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44 (1999) 598-602
47. Holt P.R. Competitive inhibition of intestinal bile salt absorption in the rat. Am J Physiol 210 (1966) 63563-63569
48. Cohen B.I., Raicht R.F., Deschner E.E., Takahashi M., Sarwal A.N., and Fazzini E. Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats. J Natl Cancer Inst 64 (1980) 573-578
49. Martinez J.D., Stratagoules E.D., LaRue J.M., Powell A.A., Gause P.R., Craven M.T., et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 31 (1998) 111-118
50. Marchetti M.C., Migliorati G., Moraca R., Riccardi C., Nicoletti I., Fabiani R., et al. Possible mechanisms involved in apoptosis of colon tumor cell lines induced by deoxycholic acid, short-chain fatty acids, and their mixtures. Nutr Cancer 28 (1997) 74-80
51. Bernstein C., Bernstein H., Garewal H., Dinning P., Jabi R., Sampliner R.E., et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 59 (1999) 2353-2357
52. Sital R., Kusters J., De Rooij F., Kuipers E., and Siersema P. Bile acids and Barrett's oesophagus: a sine qua non or coincidence?. Scand J Gastroenterol 243 Suppl (2006) 11-17
53. Pera M., Trastek V.F., Carpenter H.A., Fernandez P.L., Cardesa A., Mohr U., and Pairolero P.C. Influence of pancreatic and biliary reflux on the development of esophageal carcinoma. Ann Thorac Surg 55 (1993) 1386-1392
54. Phillips W.A., Russell S.E., Ciavarella M.L., Choong D.Y., Montgomery K.G., Smith K., et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 118 (2006) 2644-2646
55. Vona-Davis L., Frankenberry K., Cunningham C., Riggs D.R., Jackson B.J., Szwerc M.F., et al. MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro. J Surg Res 127 (2005) 53-58
56. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193-204